Roche (ROG.VX) is seeking European and U.S. backing for vemurafenib, a drug to treat the deadliest form of skin cancer, the Swiss drugmaker said on Wednesday.
Analysts have estimated the drug, which Roche wants to use to treat patients with BRAF V600 mutation-positive metastatic melanoma, will have peak sales of 500 million to 1 billion Swiss francs ($0.5-1 billion).
Sentiment towards Roche is starting to improve thanks to a string of more positive product developments this year, helping to boost investors’ confidence after they were rattled by development setbacks last year.
